Please login to the form below

Not currently logged in
Email:
Password:

Annalisa Jenkins joins biomarker firm PlaqueTec as CEO

She arrives from US-based Dimension Therapeutics, where she was CEO

Annalisa JenkinsUK-based PlaqueTec has appointed Annalise Jenkins as its chief executive officer, a role that will see her lead the 2018 launch of the biomarker-based liquid biopsy system (LBS).

Dr Jenkins joins the company from Dimension Therapeutics, where she served as its chief executive officer, and her previous roles have seen her gain expertise in scientific research, clinical development, regulatory process and commercialisation.

Jon Moynihan, chairman of PlaqueTec, said: “Dr Jenkins is a passionate and energetic leader with a proven track record of successfully translating exciting science from bench to bedside.

“We are pleased to welcome her to PlaqueTec at an important time for the company, as we will surely benefit from her extensive expertise in growing both private and public companies in the life sciences industry.”

Prior to Dimension Therapeutics, Dr Jenskins served as executive vice president, head of global research and development for Merck Serono and she has also had a nearly 15-year career at Bristol-Myers Squibb.

She said: “I look forward to working with the highly accomplished leadership team and board of directors at PlaqueTec to help advance the study and launch of its pioneering system through increased academic and biopharma collaborations.”

22nd November 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

Medical information in precision medicine
Global Medical Information Leader James Oughton reveals the top trends in medical information and precision medicine....
Australian Flu and the dilemma of naming diseases
...
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...

Infographics